Tirzepatide for diabetes vs long-acting insulins demonstrated superior glycemic control and weight loss compared among adults with type 2 diabetes.
"The analysis shows that in the SURPASS-4 trial, approximately 80% of individuals who were treated with tirzepatide and who reached an A1c of 6.5% or weight loss > 10% at 52 weeks retained those ...
Hosted on MSN1mon
Predictors for achieving, sustaining blood glucose control, weight loss with tirzepatide in adults with type 2 diabetesThe phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine (a long-acting insulin) for type 2 diabetes (T2D).
Hosted on MSN10mon
Tirzepatide Peptide And Weight-Related StudiesEffect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's ...
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback